110 likes | 208 Views
Overview of Kuros Intellectual Property. Kuros Biosurgery AG. Kuros`IP Portfolio // Fibrin Technology (FRT). Kuros licensed 10 patent families for Fibrin Technology from: Licensor No Patent Families ETH and University of Zürich 6 American Red Cross 3
E N D
Overview of Kuros Intellectual Property Kuros Biosurgery AG
Kuros`IP Portfolio // Fibrin Technology (FRT) Kuros licensed 10 patent families for Fibrin Technology from: Licensor No Patent Families ETH and University of Zürich 6 American Red Cross 3 California Institute of Technology 1 - exclusively; -in almost all fields; - worldwide
Kuros` IP Portfolio (I): in use Covalentlinking technology Growth Factor Small Bioactive Factor Degradation Site Degradation Site TG TG fibrin matrix fibrin matrix
Kuros` IP Portfolio (I): in use Growth Factor TG Granted patents US 2 (US 6,331,422; US 6,607,740) Independent claims covering: • Composition comprising fibrin network and TG-peptide. • Method of making the fibrin network plus attached TG-peptide Pending applications US: 3 PCT (EP, JP, MX, CA): 3 (US 2003/0187232; US 2004/0082513; US 2003/0166833; WO98/43686; WO 01/83522; WO 03/052091) Claims pending covering: • A kit comprising fibrinogen, factor XIIIa, thrombin and TG-bioactive factor • A kit comprising fusion peptide with PTH and crosslinkable substrate domain • Fusion protein comprising protein or peptide and a TG-domain • Fusion protein comprising bioactive factor, a TG- domain and a degradation site • Fusion peptide comprising PTH and a crosslinkable substrate domain • Various claims on matrix and methods of forming a matrix
Kuros` IP Portfolio (3): not in use Heparin Technology Concept I Concept II Growth Factor Growth Factor Heparin Heparin heparin-bdg.peptide TG TG fibrin matrix fibrin matrix
Kuros` IP Portfolio (3) Growth Factor Heparin TG Heparin concept I Granted patents: US 1 (US 6,468,731) Pending applications: US 1 (not issued) possibility to file divisionals in EP, JP, MX, CA Claims cover Fibrin matrix + TG-heparin (or heparin like) linked to matrix + heparin binding growth factor Method of making a matrix for the controlled delivery of growth factors Fusion protein comprising a two domains, first is heparin or heparin- like compound, second is factor XIIIa substrate domain coupled to the first domain
Growth Factor Heparin HB-peptide TG Kuros` IP Portfolio (3) Heparin concept II Granted patents: US 1 (US 6,723,344) Pending applications: US 1 (US 2001/0020086, allowed ; WO 00/64481)) Claimscover: Fusion protein comprising a growth factor domain and a heparin binding domain Method of making a matrix by adding (i) TG-heparin binding peptide (ii) heparin and (iii) a heparin binding growth factor Fibrin matrix + TG-heparin binding peptide linked to matrix+ heparin or heparin like compound + heparin binding growth factor
Kuros IP Portfolio (2): in use ARC and Kuros „mixing-in“ technology Deglycosylated growth factor Small bioactive Factor Growth Factor fibrin matrix
Kuros IP Portfolio (2): in use ARC number of applications - granted therefrom: (see summary) US 8 ; AU 3 (granted 1); CA 3; EP 4 (granted 2); JP 3 (granted 1) Broadest claims cover: Delivery system from a fibrin matrix with a sustained release time period greater than that achieved by simple diffusion; bioactive factor in matrix above its solubility level (various applications and patents cover a variety of biocative factors) Method for treating wounded tissue with an unsupplemented fibrin sealant powder (no fibrinolysis inhibitor) Fibrin plus DBM/BMP Fibrin sealant bandage without any supplements Fibrin sealant foam comprising fibrinogen and an agent which causes fibrinogen to foam
Kuros IP Portfolio: in use // SRT Technology A + B : monomeric polyethylenglycol molecules C: network of A +B B A : bioactive factor • Granted US patent : 1 • Pending: 2 US, EP, JP, CA, MX, AU • 1. biomaterial formed by the particular kind of monomers, method of formation and use. • particular linker chemistry of bioactive factors to the biomaterial to allow sustained delivery • 3. The particular gel architecture and molecules in use C
Vertebroplasty Principle: same as for SRT Technology however different monomers. Pending applications in US and PCT Claims: Use of a two-component composition for hard tissue augmentation, biomaterial, kit of parts, in-situ crosslinkable composition PCT examination report positive on the broad use claim.